Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State‐of‐the‐Art Review

International Journal of Pharmaceutics

Volumn 547, Issue 1-2, 2018, Pages 209-225

  Patil, Tulshidas S ^a   Deshpande, Ashwini S ^a  

^a School of Pharmacy and Technology Management   (India)

Author keywords

Lung diseases; Nanostructured lipid carriers; Pulmonary targeting; Surface engineering

Indexed keywords

LIGAND; LIPID; NANOCARRIER; NANOMATERIAL; DRUG CARRIER;

ACUTE LUNG INJURY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FIBROSING ALVEOLITIS; HUMAN; LUNG CANCER; LUNG DISEASE; LUNG INFECTION; LUNG TUBERCULOSIS; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DRUG DESIGN; MEDICINAL CHEMISTRY; PROCEDURES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIPIDS; LUNG DISEASES; NANOSTRUCTURES;

EID: 85047826352     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2018.05.070     Document Type: Review

References (114)

1. Amore, E., Ferraro, M., Manca, M.L., Gjomarkaj, M., Giammona, G., Pace, E., Bondì M.L., Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment. Nanomedicine 12:19 (2017), 2287–2302.
2. Ando, S., Putnam, D., Pack, D.W., Langer, R., PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. 88 (1999), 126–130.
3. Athanazio, R., Airway disease: similarities and differences between asthma, COPD and bronchiectasis. Clinics 67 (2012), 1335–1343.
4. Cheng, Y.S., Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech 15 (2014), 630–640.
5. Chinsriwongkul, A., Chareanputtakhun, P., Ngawhirunpat, T., Rojanarata, T., Sila-on, W., Ruktanonchai, U., Opanasopit, P., Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech 13 (2012), 150–158.
6. da Silva, A.L., Cruz, F.F., Rocco, P.R.M., Morales, M.M., New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys. Rev. 9 (2017), 793–803.
7. Darbandi, M.A., Rouholamini, N., Gilani, K., Tajerzadeh, H., The effect of vehicles on spray drying of rifampicin inhalable microparticles: in vitro and in vivo evaluation. DARU 16 (2008), 128–135.
8. Davies, L.A., Nunez-Alonso, G.A., McLachlan, G., Hyde, S.C., Gill, D.R., Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. Hum. Gene Ther. CL Dev. 25 (2014), 97–107.
9. De Leo, V., Ruscigno, S., Trapani, A., Di Gioia, S., Milano, F., Mandracchia, D., Comparelli, R., Castellani, S., Agostiano, A., Trapani, G., Catucci, L., Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases. Int. J. Pharm. 545 (2018), 378–388.
10. Desu, H.R., Thoma, L.A., Wood, G.C., Nebulization of cyclic arginine-glycine-(D)-aspartic acid-peptide grafted and drug encapsulated liposomes for inhibition of acute lung injury. Pharm. Res., 35, 2018, 94.
11. Doktorovova, S., Souto, E.B., Silva, A.M., Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87 (2014), 1–18.
12. Doktorovova, S., Kovacevic, A.B., Garcia, M.L., Souto, E.B., Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 108 (2016), 235–252.
13. Du, J., Li, L., Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?. Drug Deliv. 23 (2016), 1799–1809.
14. Ehsan, Z., Wetzel, J.D., Clancy, J.P., Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Expert. Opin. Invest. Drugs 23 (2014), 743–749.
15. El-Salamouni, N.S., Farid, R.M., El-Kamel, A.H., El-Gamal, S.S., Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int. J. Pharm. 496 (2015), 976–983.
16. Fiegel, J., Garcia-Contreras, L., Thomas, M., VerBerkmoes, J., Elbert, K., Hickey, A., Edwards, D., Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 25 (2008), 805–811.
17. Food and Drug Administration, U.S.A., 1998. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products: Chemistry, Manufacturing and Controls Documentation—Draft Guidance for Industry.
18. Gad, S., Tajber, L., Corrigan, O.I., Healy, A.M., Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state. J. Pharm. Pharmacol. 64 (2012), 1264–1274.
19. Garbuzenko, O.B., Ivanova, V., Kholodovych, V., Reimer, D.C., Reuhl, K.R., Yurkow, E., Adler, D., Minko, T., Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomedicine 13 (2017), 1983–1992.
20. Garcia, F.D.M., Nanomedicine and therapy of lung diseases. Einstein (São Paulo) 12 (2014), 531–533.
21. Garcia-Contreras, L., Padilla-Carlin, D.J., Sung, J., VerBerkmoes, J., Muttil, P., Elbert, K., Peloquin, C., Edwards, D., Hickey, A., Pharmacokinetics of ethionamide delivered in spray-dried microparticles to the lungs of guinea pigs. J. Pharm. Sci. 106 (2017), 331–337.
22. Global initiative for Asthma (GINA), 2016. http://ginasthma.org/ (accessed 9 April 2018).
23. Grand View Research, USA, 2017. Pulmonary Drug Delivery Devices/Systems Market Analysis By Product (MDIs, DPIs, Nebulizers, Accessories), By Application, By Distribution Channel, By End-use, And Segment Forecasts, 2018–2025. https://www.grandviewresearch.com/industry-analysis/pulmonary-drug-delivery-systems-market (accessed 9 April 2018).
24. Han, Y., Li, Y., Zhang, P., Sun, J., Li, X., Sun, X., Kong, F., Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm. Dev. Technol. 21 (2016), 277–281.
25. Islan, G.A., Tornello, P.C., Abraham, G.A., Duran, N., Castro, G.R., Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization. Colloids Surf. B 143 (2016), 168–176.
26. Ivanova, V., Garbuzenko, O.B., Reuhl, K.R., Reimer, D.C., Pozharov, V.P., Minko, T., Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur. J. Pharm. Biopharm. 84 (2013), 335–344.
27. Iyer, R., Hsia, C.C., Nguyen, K.T., Nano-therapeutics for the lung: state-of-the-art and future perspectives. Curr. Pharm. Des. 21 (2015), 5233–5244.
28. Jaafar-Maalej, C., Andrieu, V., Elaissari, A., Fessi, H., Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: preparation, characterization and in vitro drug release. J. Nanosci. Nanotechnol. 11 (2011), 1841–1851.
29. Jaafar-Maalej, C., Elaissari, A., Fessi, H., Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin. Drug Deliv. 9 (2012), 1111–1127.
30. Johnson, E.R., Matthay, M.A., Acute lung injury: epidemiology, pathogenesis, and treatment. J. Aerosol Med. Pulm. Drug Deliv. 23 (2010), 243–252.
31. Jyoti, K., Kaur, K., Pandey, R.S., Jain, U.K., Chandra, R., Madan, J., Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies. J. Colloid Interface. Sci. 445 (2015), 219–230.
32. Kardara, M., Hatziantoniou, S., Sfika, A., Vassiliou, A.G., Mourelatou, E., Muagkou, C., Armaganidis, A., Roussos, C., Orfanos, S.E., Kotanidou, A., Maniatis, N.A., Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury. Pharm. Res. 30 (2013), 1836–1847.
33. Kaur, P., Garg, T., Rath, G., Murthy, R.S., Goyal, A.K., Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of paclitaxel for the management of drug resistance lung cancer using Box-Behnken design. Drug Deliv. 23 (2016), 1912–1925.
34. Khan, R.D., The use of nanocarriers for drug delivery in cancer therapy. J. Cancer Sci. Ther. 2 (2010), 058–062.
35. Khan, D.R., Webb, M.N., Cadotte, T.H., Gavette, M.N., Use of targeted liposome-based chemotherapeutics to treat breast cancer. Breast Cancer 9 (2015), 1–5.
36. Konduri, K.S., Nandedkar, S., Düzgünes, N., Suzara, V., Artwohl, J., Bunte, R., Gangadharam, P.R., Efficacy of liposomal budesonide in experimental asthma. J. Allergy Clin. Immunol. 111 (2003), 321–327.
37. Kurmi, B.D., Kayat, J., Gajbhiye, V., Tekade, R.K., Jain, N.K., Micro-and nanocarrier-mediated lung targeting. Expert Opin. Drug Deliv. 7 (2010), 781–794.
38. Kuzmov, A., Minko, T., Nanotechnology approaches for inhalation treatment of lung diseases. J. Control Release 219 (2015), 500–518.
39. Labiris, N.R., Dolovich, M.B., Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56 (2003), 588–599.
40. Li, S.J., Wang, X.J., Hu, J.B., Kang, X.Q., Chen, L., Xu, X.L., Ying, X.Y., Jiang, S.P., Du, Y.Z., Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy. Drug Deliv. 24 (2017), 402–413.
41. Li, N., Weng, D., Wang, S.M., Zhang, Y., Chen, S.S., Yin, Z.F., Zhai, J., Scoble, J., Williams, C.C., Chen, T., Qiu, H., Surfactant protein-A nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury. Drug Deliv. 24:1 (2017), 1770–1781.
42. Liang, Z., Ni, R., Zhou, J., Mao, S., Recent advances in controlled pulmonary drug delivery. Drug Discov. Today 20 (2015), 380–389.
43. Liang, Y., Tian, B., Zhang, J., Li, K., Wang, L., Han, J., Wu, Z., Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer. Int. J. Nanomed. 12 (2017), 1699–1715.
44. Lin, C., Zhang, X., Chen, H., Bian, Z., Zhang, G., Riaz, M.K., Tyagi, D., Lin, G., Zhang, Y., Wang, J., Lu, A., Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Drug Deliv. 25 (2018), 256–266.
45. Maitra, A., Kumar, V., The lung. Kumar, V., Abbas, A.K., Aster, J.C., (eds.) Robbins Basic Pathology, 2017, Elsevier Health Sciences, Pennsylvania, 479–539.
46. MedlinePlus: U. S. National Library on Medicine U.S.A., 2018a. Lung Diseases. https://medlineplus.gov/lungdiseases.html#summary (accessed 9 April 2018).
47. MedlinePlus: U. S. National Library on Medicine U.S.A., 2018b. Lung Cancer. https://medlineplus.gov/lungcancer.html (accessed 9 April 2018).
48. Mishra, P., Nayak, B., Dey, R.K., PEGylation in anti-cancer therapy: an overview. Asian J. Pharm. 11 (2016), 337–348.
49. Momin, M.A., Sinha, S., Tucker, I.G., Doyle, C., Das, S.C., Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. Int. J. Pharm. 528 (2017), 107–117.
50. Moreau-Marquis, S., Stanton, B.A., O'Toole, G.A., Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther. 21 (2008), 595–599.
51. Moreno-Sastre, M., Pastor, M., Esquisabel, A., Sans, E., Vinas, M., Bachiller, D., Pedraz, J.L., Stability study of sodium colistimethate-loaded lipid nanoparticles. J. Microencapsul. 33 (2016), 636–645.
52. Moreno-Sastre, M., Pastor, M., Esquisabel, A., Sans, E., Vinas, M., Fleischer, A., Palomino, E., Bachiller, D., Pedraz, J.L., Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int. J. Pharm. 498 (2016), 263–273.
53. Muller, R.H., Radtke, M., Wissing, S.A., Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242 (2002), 121–128.
54. Muralidharan, P., Malapit, M., Mallory, E., Hayes, D. Jr., Mansour, H.M., Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine 11 (2015), 1189–1199.
55. Mussi, S.V., Silva, R.C., de Oliveira, M.C., Lucci, C.M., de Azevedo, R.B., Ferreira, L.A.M., New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur. J. Pharm. Sci. 48 (2013), 282–290.
56. National Institutes of Health (NIH): National heart, lung and blood institute U.S.A., 2018a. Asthma. https://www.nhlbi.nih.gov/health/health-topics/topics/asthma (accessed 9 April 2018).
57. National Institutes of Health (NIH): National heart, lung and blood institute U.S.A, 2018b. Acute Respiratory Distress Syndrome (ARDS). https://www.nhlbi.nih.gov/health/health-topics/topics/ards (accessed 9 April 2018).
58. National Institutes of Health (NIH): National heart, lung and blood institute U.S.A., 2018c. Idiopathic Pulmonary Fibrosis. https://www.nhlbi.nih.gov/health/health-topics/topics/ipf/ (accessed 9 April 2018).
59. Omlor, A.J., Nguyen, J., Bals, R., Dinh, Q.T., Nanotechnology in respiratory medicine. Respir. Res., 16, 2015, 64.
60. Paranjpe, M., Muller-Goymann, C.C., Nanoparticle-mediated pulmonary drug delivery: a review. Int. J. Mol. Sci. 15 (2014), 5852–5873.
61. Pardeike, J., Weber, S., Haber, T., Wagner, J., Zarfl, H.P., Plank, H., Zimmer, A., Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int. J. Pharm. 419 (2011), 329–338.
62. Parmar, J.J., Singh, D.J., Hegde, D.D., Lohade, A.A., Soni, P.S., Samad, A., Menon, M.D., Development and evaluation of inhalational liposomal system of budesonide for better management of asthma. Indian J. Pharm. Sci., 72, 2010, 442.
63. Pastor, M., Moreno-Sastre, M., Esquisabel, A., Sans, E., Vinas, M., Bachiller, D., Asensio, V.J., Pozo, A.D., Gainza, E., Pedraz, J.L., Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int. J. Pharm. 477 (2014), 485–494.
64. Patel, A.R., Chougule, M.B.I.T., Patlolla, R., Wang, G., Singh, M., Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm. Res. 30 (2013), 1435–1446.
65. Patil, T.S., Deshpande, A.S., Deshpande, S., Critical review on the analytical methods for the estimation of clofazimine in bulk, biological fluids and pharmaceutical formulations. Crit. Rev. Anal. Chem. 48 (2018), 492–502.
66. Patil, T.S., Deshpande, A.S., Deshpande, S., Shende, P., Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. J. Drug Target., 1–16, 2018, 10.1080/1061186X.2018.1455842.
67. Patil, J.S., Devi, V.K., Devi, K., Sarasija, S., A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis. Lung India 32 (2015), 331–338.
68. Patil-Gadhe, A., Kyadarkunte, A., Patole, M., Pokharkar, V., Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. Eur. J. Pharm. Biopharm. 88 (2014), 169–177.
69. Patil-Gadhe, A., Pokharkar, V., Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach. Pulm. Pharmacol. Ther. 27 (2014), 197–207.
70. Patil-Gadhe, A., Pokharkar, V., Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: Optimization by factorial design. Int. J. Pharm. 501 (2016), 199–210.
71. Patlolla, R.R., Chougule, M., Patel, A.R., Jackson, T., Tata, P.N., Singh, M., Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control Release 144 (2010), 233–241.
72. Pawar, S.K., Vavia, P., Efficacy interactions of PEG–DOX–N-acetyl glucosamine prodrug conjugate for anticancer therapy. Eur. J. Pharm. Biopharm. 97 (2015), 454–463.
73. Pawar, S.K., Badhwar, A.J., Kharas, F., Khandare, J.J., Vavia, P.R., Design, synthesis and evaluation of N-acetyl glucosamine (NAG)–PEG–doxorubicin targeted conjugates for anticancer delivery. Int. J. Pharm. 436 (2012), 183–193.
74. Pillai, G., Nanomedicines for cancer therapy: an update of FDA approved and those under various stages of development. SOJ. Pharm. Pharm. Sci., 1, 2014, 13.
75. Pinheiro, M., Ribeiro, R., Vieira, A., Andrade, F., Reis, S., Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des. Devel. Ther. 10 (2016), 2467–2475.
76. Pison, U., Welte, T., Giersig, M., Groneberg, D.A., Nanomedicine for respiratory diseases. Eur. J. Pharmacol. 533 (2006), 341–350.
77. Pourshahab, P.S., Gilani, K., Moazeni, E., Eslahi, H., Fazeli, M.R., Jamalifar, H., Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J. Microencapsul. 28 (2011), 605–613.
78. Price, D.N., Kunda, N.K., Muttil, P., Challenges associated with the pulmonary delivery of therapeutic dry powders for preclinical testing. KONA Powder Part. J., 2018, 10.14356/kona.2019008.
79. Ragaller, M., Richter, T., Acute lung injury and acute respiratory distress syndrome. J. Emerg. Trauma Shock 3 (2010), 43–51.
80. Ratjen, F., Brockhaus, F., Angyalosi, G., Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J. Cyst. Fibros. 8 (2009), 361–369.
81. Rawal, T., Parmar, R., Tyagi, R.K., Butani, S., Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. Colloids Surf. B Biointerfaces 154 (2017), 321–330.
82. Rojanarat, W., Changsan, N., Tawithong, E., Pinsuwan, S., Chan, H.K., Srichana, T., Isoniazid proliposome powders for inhalation—preparation, characterization and cell culture studies. Int. J. Mol. Sci. 12 (2011), 4414–4434.
83. Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., Srichana, T., Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv. 19 (2012), 334–345.
84. Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., Srichana, T., Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics 4 (2012), 385–412.
85. Russell, V., Four challenges for pulmonary drug delivery. Pharm. Technol. 4 (2017), s16–s18.
86. Sans-Serramitjana, E., Fuste, E., Martinez-Garriga, B., Merlos, A., Pastor, M., Pedraz, J.L., Esquisabel, A., Bachiller, D., Vinuesa, T., Vinas, M., Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J. Cyst. Fibros. 15 (2016), 611–618.
87. Sato, M.R., Oshiro Junior, J.A., Machado, R.T., de Souza, P.C., Campos, D.L., Pavan, F.R., da Silva, P.B., Chorilli, M., Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug Des. Dev. Ther. 11 (2017), 909–921.
88. Shao, Z., Shao, J., Tan, B., Guan, S., Liu, Z., Zhao, Z., He, F., Zhao, J., Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int. J. Nanomed. 10 (2015), 1223–1233.
89. Silva, L.F.C., Kasten, G., de Campos, C.E.M., Chinelatto, A.L., Lemos-Senna, E., Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. Powder Technol. 239 (2013), 183–192.
90. Sinha, B., Mukherjee, B., Pattnaik, G., Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine 9 (2013), 94–104.
91. Smola, M., Vandamme, T., Sokolowski, A., Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomed. 3 (2008), 1–19.
92. Song, X., Lin, Q., Guo, L., Fu, Y., Han, J., Ke, H., Sun, X., Gong, T., Zhang, Z., Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery. Pharm. Res. 32 (2015), 1741–1751.
93. Sung, J.C., Padilla, D.J., Garcia-Contreras, L., VerBerkmoes, J.L., Durbin, D., Peloquin, C.A., Elbert, K.J., Hickey, A.J., Edwards, D.A., Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 26 (2009), 1847–1855.
94. Tang, J., Li, J., Li, G., Zhang, H., Wang, L., Li, D., Ding, J., spermidine-mediated poly (lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis. Int. J. Nanomed. 12 (2017), 6687–6704.
95. Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O.B., Minko, T., Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control Release 171 (2013), 349–357.
96. Tiberi, S., Buchanan, R., Caminero, J.A., Centis, R., Arbex, M.A., Salazar, M., Potter, J., Migliori, G.B., The challenge of the new tuberculosis drugs. Presse Med. 46 (2017), e41–e51.
97. Togami, K., Miyao, A., Miyakoshi, K., Kanehira, Y., Tada, H., Chono, S., Efficient delivery to human lung fibroblasts (WI-38) of pirfenidone incorporated into liposomes modified with truncated basic fibroblast growth factor and its inhibitory effect on collagen synthesis in idiopathic pulmonary fibrosis. Biol. Pharm. Bull. 38 (2015), 270–276.
98. Trivedi, R., Redente, E.F., Thakur, A., Riches, D.W., Kompella, U.B., Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology, 23, 2012, 505101.
99. van Rijt, S.H., Bein, T., Meiners, S., Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respir J. 44 (2014), 765–774.
100. Varshosaz, J., Ghaffari, S., Mirshojaei, S.F., Jafarian, A., Atyabi, F., Kobarfard, F., Azarmi, S., Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed. Res. Int. 2013 (2013), 1–8.
101. Verma, R.K., Germishuizen, W.A., Motheo, M.P., Agrawal, A.K., Singh, A.K., Mohan, M., Gupta, P., Gupta, U.D., Cholo, M., Anderson, R., Fourie, P.B., Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob. Agents Chemother. 57 (2013), 1050–1052.
102. Wang, Y., Zhang, H., Hao, J., Li, B., Li, M., Xiuwen, W., Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv. 23 (2016), 1398–1403.
103. Wang, W., Zhu, R., Xie, Q., Li, A., Xiao, Y., Li, K., Liu, H., Cui, D., Chen, Y., Wang, S., Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int. J. Nanomed. 7 (2012), 3667–3677.
104. Weber, S., Zimmer, A., Pardeike, J., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur. J. Pharm. Biopharm. 86 (2014), 7–22.
105. World Health Organization. Global Tuberculosis Report 2016. http://apps.who.int/medicinedocs/en/d/Js23098en/ Last date accessed: 21st may 2018.
106. World Health Organization. The top 10 causes of death. http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death Last date accessed: 21st may 2018.
107. World Health Organization. The top 10 causes of death; Leading causes of death by economy income group. http://www.who.int/mediacentre/factsheets/fs310/en/index1.html Last date accessed: 21st may 2018.
108. Xiao, X., Zeng, X., Zhang, X., Ma, L., Liu, X., Yu, H., Mei, L., Liu, Z., Effects of Caryota mitis profilin-loaded PLGA nanoparticles in a murine model of allergic asthma. Int. J. Nanomed., 8, 2013, 4553.
109. Xu, H., He, C., Liu, Y., Jiang, J., Ma, T., Novel therapeutic modalities and drug delivery–erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif. Cells Nanomed. Biotechnol., 2017, 1–6.
110. Yang, W.K., Lee, C.H., Kim, M.H., Kim, S.H., Choi, H.Y., Yeo, Y., Park, Y.C., Effects of inhalable microparticles of Seonpyejeongcheon-tang in an asthma mouse model: effects of microparticles of SJT. J. Pharmacopuncture, 19, 2016, 303.
111. Yang, R., Yang, S.G., Shim, W.S., Cui, F., Cheng, G., Kim, I.W., Kim, D.D., Chung, S.J., Shim, C.K., Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J. Pharm. Sci. 98 (2009), 970–984.
112. Yhee, J.Y., Im, J., Nho, R.S., Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery. J. Clin. Med., 5, 2016, 82.
113. Zhang, X., Gan, Y., Gan, L., Nie, S., Pan, W., PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J. Pharm. Pharmacol. 60 (2008), 1077–1087.
114. Zhang, B., Zhang, Y., Yu, D., Lung cancer gene therapy: Transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol. Rep. 37 (2017), 937–944.